Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control
- Jennifer A. Hirst, MSC1,
- Andrew J. Farmer, MD1,
- Raghib Ali, MSC2,3,
- Nia W. Roberts, MSC4 and
- Richard J. Stevens, PHD1
- 1Department of Primary Care Health Sciences, University of Oxford, Oxford, U.K., and the National Institute for Health Research School for Primary Care Research, Oxford, U.K.
- 2Cancer Epidemiology Unit, University of Oxford, Oxford, U.K.
- 3Department of Community Medicine, United Arab Emirates University, Al Ain, United Arab Emirates
- 4Bodleian Health Care Libraries, University of Oxford, Oxford, U.K.
- Corresponding author: Jennifer A. Hirst, .
OBJECTIVE Metformin is the first-line oral medication recommended for glycemic control in patients with type 2 diabetes. We reviewed the literature to quantify the effect of metformin treatment on glycated hemoglobin (HbA1c) levels in all types of diabetes and examine the impact of differing doses on glycemic control.
RESEARCH DESIGN AND METHODS MEDLINE, EMBASE, and the Cochrane Library were searched from 1950 to June 2010 for trials of at least 12 weeks’ duration in which diabetic patients were treated with either metformin monotherapy or as an add-on therapy. Data on change in HbA1c were pooled in a meta-analysis. Data from dose-comparison trials were separately pooled.
RESULTS A total of 35 trials were identified for the main analysis and 7 for the dose-comparison analysis. Metformin monotherapy lowered HbA1c by 1.12% (95% CI 0.92–1.32; I2 = 80%) versus placebo, metformin added to oral therapy lowered HbA1c by 0.95% (0.77–1.13; I2 = 77%) versus placebo added to oral therapy, and metformin added to insulin therapy lowered HbA1c by 0.60% (0.30–0.91; I2 = 79.8%) versus insulin only. There was a significantly greater reduction in HbA1c using higher doses of metformin compared with lower doses of metformin with no significant increase in side effects.
CONCLUSIONS Evidence supports the effectiveness of metformin therapy in a clinically important lowering of HbA1c used as monotherapy and in combination with other therapeutic agents. There is potential for using higher doses of metformin to maximize glycemic control in diabetic patients without increasing gastrointestinal effects.
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1465/-/DC1.
The views expressed by the authors may not necessarily reflect the views or policies of the National Institute for Health Research.
- Received August 3, 2011.
- Accepted October 31, 2011.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.